- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02460692
Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain
A Randomized Controlled Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92103
- UC Center for Medicinal Cannabis Research, UC San Diego
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Age greater than 18. Presence of chronic low back pain (CLBP) defined as the response to two questions 1) How long has back pain been an ongoing problem for you? 2) How often has low back pain been an ongoing problem for you over the past 6 months? A response of greater than 3 months to question 1 and a response of "at least half the days in the past 6 months" to question 2 will define CLBP according to the NIH Task Force on Research Standards for Chronic Low Back Pain.
The numerical pain intensity must be greater than 3/10 each day during the one-week observation period.
To avoid confounding by concurrent medications, participants will have had a stable analgesic regimen that they will continue throughout the study To obviate residual neuropsychological effects from cannabis exposure, participants will be abstinent from this herbal medicine for 7 days prior to study entry.
Exclusion Criteria:
Presence of another painful condition of greater severity than the neuropathic pain condition which is being studied.
History of traumatic brain injury. Clinically significant or unstable medical condition. Individuals with significant cardiovascular, hepatic or renal disease, uncontrolled hypertension, and chronic pulmonary disease (eg, asthma, COPD), will be excluded. If warranted clinically, subjects will undergo laboratory evaluation (blood chemistry, electrocardiogram, urinalysis, toxicology screening for confirmation. Females of childbearing potential will undergo pregnancy testing.
A positive result on toxicity screening will exclude individuals from participation. A urine drug test that screens for 5 categories of drugs: marijuana (Δ9-THC), cocaine, amphetamines/methamphetamines, opiates, benzodiazepines and phencyclidine (PCP) will be employed. A positive result for opioids and/or THC will not be exclusionary if the patient is receiving a prescription for an opioid and/or THC.
Allergy to sesame oil, lactose, or gelatin Vascular disease, especially Raynauld's syndrome, systolic blood pressure > 170 mm, diastolic blood pressure > 100 mm Recent injuries to the upper extremity Cognitive impairment, such as Dementia or Alzheimer's Disease Substance Abuse History: The Substance Abuse Module of the Diagnostic Interview Schedule for the Diagnostic and Statistical Manual (DSM)-IV will be administered to exclude individuals with current substance use disorders.
Pregnancy as ascertained by a mandatory commercial pregnancy test Past history of suicide attempt. Cannabis can exacerbate pre-existing schizophrenia, and has been linked to an increase in the risk of suicide in such patients. In patients with bipolar disorder, cannabis use has been associated with worsening of manic and psychotic symptoms. Such findings suggest that cannabis is contraindicated in individuals with serious mental health issues, a line of reasoning that will be observed in the present study by excluding patients in the bipolar/schizoaffective/schizophrenic spectrum.
Suicidality. Exposure to cannabis does not lead to depression but it may be associated with suicidal thoughts and attempts. Therefore, the Beck Depression Inventory (BDI)-II will be used to measure suicidal ideation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebos
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6%
CBD) can maintain an analgesic response over an eight week period compared to placebo.
|
Administration of vaporized cannabis plus either dronabinol or placebo pill
Other Names:
|
Active Comparator: Dronabinol
A direct comparison of cannabis and dronabinol has not been performed in a clinical population.
The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
|
Administration of vaporized cannabis plus either dronabinol or placebo pill
Other Names:
|
Experimental: Vaporized Cannabis 3.7% THC/5.6% CBD
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD)
and dronabinol.
We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
|
Administration of vaporized cannabis plus either dronabinol or placebo pill
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numerical Pain Intensity
Time Frame: 8 weeks
|
The primary outcome is self-reported daily average numerical pain intensity during the past 24 hours.
The numerical pain intensity is an 11-point pain intensity numerical rating scale (PI-NRS), where 0 equals no pain and 10 equals worst possible pain.
The time frame includes baseline and weeks 1, 3, 5, 7, 8. Baseline is the pain tensity reported at the first day in the daily diary, before the first dose.
The follow-up pain intensities (weeks 1, 3, 5, 7, 8) are the daily diary average pain intensities since the previously reported timepoint.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)
Time Frame: 8 weeks
|
A Task Force was convened by the NIH Pain Consortium, with the goal of developing research standards for chronic low back pain.
The results included recommendations for a repeated measures dataset in order to establish greater consistency in reporting in order to facilitate comparisons among studies.
The repeated measure minimal dataset is based upon scores based upon the Patient-Reported Outcomes Measurement Information System ® (PROMIS).
These items yield a classification of impacts on the lives of patients that range from 1 (least impact) to 42 (greatest impact).
|
8 weeks
|
Neuropathic Pain Scale
Time Frame: 8 weeks
|
The Neuropathic Pain Scale (NPS) is an 11-point numerical scale consisting of 13 questions that ask ratings of various pain descriptors (including pain intensity, sharpness, burning, aching, cold, sensitivity, itching,unpleasantness, deep, and surface pain).
The NPS is scored as the sum of these pain descriptors.
Range of scores is from 0 to100.
A higher score is a worse score.
|
8 weeks
|
Hopkins Verbal Learning Test
Time Frame: 8 weeks
|
The Hopkins Verbal Learning Test provides information on the ability to learn and immediately recall verbal information across trials, as well at the ability to retain, reproduce, and recognize this information after a delay. A list of 12 words is presented to the subject over three trials. After each trial, the subject is to recall as many items as possible from the list in any desired order. A 20-minute delay follows the administration of the three trials, after which the subject is asked to recall the list. The ability to learn is represented by the number of correct words, with a score range of 0-36. A higher score indicates better performance. |
8 weeks
|
Grooved Pegboard Test - Dominant Hand
Time Frame: 8 weeks
|
The Grooved Pegboard Test is a test of fine motor coordination and speed.
Subjects are required to place 25 small metal pegs into holes on a 3" x 3" metal board.
All pegs are alike and have a ridge on one side, which corresponds to a notch in each hole on the board.
First the dominant hand is tested, and subjects are asked to place the pegs in the holes as fast as they can.
This is then repeated with the non-dominant hand, and the total time for each hand is recorded.
A higher score indicates worse performance.
|
8 weeks
|
Wechsler Adult Intelligence Scale-III Digit Symbol Test
Time Frame: 8 weeks
|
The Digit Symbol test measures concentration, psychomotor speed, and graphomotor abilities.
This pen and paper test involves having subjects substitute a series of symbols with numbers as quickly and accurately as possible during a 120 second period.
The results are expressed as the number of correct substitutions with a score range of 0-133.
A higher number indicates better performance.
|
8 weeks
|
Profile of Mood States
Time Frame: 8 weeks
|
This questionnaire contains 65 words/statements that describe feelings people have. The questionnaire requires the patient to indicate for each word or statement how he or she has been feeling in the past week. There are 6 subscales: tension-anxiety (9 items, score range: 0-36), depression (15 items, range 0-60), anger-hostility (12 items, range 0-48), vigor-activity (8 items, range 0-32), fatigue (7 items, range 0-28), confusion-bewilderment (7 items, range 0-28). The total mood disturbance (TMD) is calculated by adding the scores for tension-anxiety, depression, anger-hostility, fatigue and confusion-bewilderment and then subtracting the score for vigor-activity. The TMD is reported and has a score range of -32 to 200. A higher score indicates worse symptoms. |
8 weeks
|
Beck Depression Inventory II
Time Frame: 8 weeks
|
The Beck Depression Inventory is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex.
Range of scores is from 0 to 63.
A higher score is a worse score.
|
8 weeks
|
Locally Developed Psychoactive Effect Scale - Good Drug Effect
Time Frame: 6 hours
|
Visual Analogue Scale (VAS) ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel ___after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. A good drug effect is presented. Range of scores is from 0 to 100. A higher score is a worse score. |
6 hours
|
Marijuana Subscale (M-scale) of the Addiction Research Center Inventory
Time Frame: 8 weeks
|
The Marijuana subscale (M-scale) of the Addiction Research Center Inventory consists of 12 true or false questions corresponding to symptoms of cannabis intoxication; the minimum and maximum scores are 0 and 12 respectively.
A higher score indicates a worse score.
The questions were rephrased to evaluate the experience from the past week rather than an acute response to cannabis.
|
8 weeks
|
Cold Pressor Test - Pain Sensitivity
Time Frame: 8 weeks
|
Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min.
During this time, blood pressure and heart rate will be measured.
After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures.
Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion.
They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point.
Maximum immersion time will be 2 min.
Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded.
Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath.
|
8 weeks
|
Cannabis Withdrawal Scale - Withdrawal Intensity
Time Frame: Week 8 and Week 10
|
The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep).
Range of scores for withdrawal intensity is from 0 to 190.
A higher score is a worse score.
|
Week 8 and Week 10
|
Driving Simulation (Lane Tracking)
Time Frame: 270 minutes
|
Lane Tracking: This task requires subjects to drive down a straight 2-lane road, maintain a constant speed of 55 mph, maintain appropriate lane position, and respond to divided attention tasks in the upper corners of the screen. The primary outcome is standard deviation of lateral deviation (swerving) with a score range of 0.51 - 3.24. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy. |
270 minutes
|
Driving Simulation (Car Following)
Time Frame: 270 minutes
|
Car Following: This simulation examines the participant's ability to closely match the speed of an automobile in front of them. Participants are to follow a lead vehicle at a safe and constant distance. The primary outcome is coherence between the participant and lead cars (a general correlation [0-1] of the participant's ability to accurately track the speed variations of the lead car. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy. |
270 minutes
|
Locally Developed Psychoactive Effect Scale - High
Time Frame: 6 hours
|
A total of 15 separate VAS ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel ___after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. Drug "high" will be presented. Range of scores is from 0 to 100. A higher score is a worse score. |
6 hours
|
Cannabis Withdrawal Scale - Negative Impact of Withdrawal
Time Frame: Week 8, Week 10
|
The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep).
The outcome is measured during the tapering period (weeks 8 and 10), at which patients slowly withdrew from medication over two weeks.
Range of scores for the negative impact of withdrawal is from 0 to 190.
A higher score is a worse score.
|
Week 8, Week 10
|
Cold Pressor Test - Pain Tolerance
Time Frame: 8 weeks
|
Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min.
During this time, blood pressure and heart rate will be measured.
After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures.
Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion.
They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point.
Maximum immersion time will be 2 min.
Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded.
Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath.
|
8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Thomas D Marcotte, PhD, UC San Diego
Publications and helpful links
General Publications
- Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008 Jun;9(6):506-21. doi: 10.1016/j.jpain.2007.12.010. Epub 2008 Apr 10.
- Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013 Feb;14(2):136-48. doi: 10.1016/j.jpain.2012.10.009. Epub 2012 Dec 11.
- Wilsey B, Atkinson JH, Marcotte TD, Grant I. The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document. Clin J Pain. 2015 Dec;31(12):1087-96. doi: 10.1097/AJP.0000000000000145.
- Grant I, Atkinson JH, Gouaux B, Wilsey B. Medical marijuana: clearing away the smoke. Open Neurol J. 2012;6:18-25. doi: 10.2174/1874205X01206010018. Epub 2012 May 4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Nervous System Diseases
- Substance-Related Disorders
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Back Pain
- Low Back Pain
- Neuralgia
- Marijuana Abuse
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Psychotropic Drugs
- Hallucinogens
- Cannabinoid Receptor Agonists
- Cannabinoid Receptor Modulators
- Dronabinol
Other Study ID Numbers
- 1R01DA038634-01A1 (U.S. NIH Grant/Contract)
- R01DA038634 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Back Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
University School of Physical Education in WroclawCompletedLow Back Pain | Low Back Pain, Mechanical | Low Back Pain, PosturalPoland
-
Texas Woman's UniversityTexas Physical Therapy AssociationCompletedLow Back Pain | Chronic Low Back Pain | Subacute Low Back PainUnited States
-
University of ParmaKing's College London; Helmholtz Zentrum München; GENOS; Ip Research Consulting... and other collaboratorsUnknownChronic Low Back Pain | Acute Low Back PainUnited States, Australia, Belgium, Croatia, Italy, United Kingdom
-
Apsen Farmaceutica S.A.CompletedLow Back Pain | Low Back Pain, Mechanical | Acute Low Back PainBrazil
-
Universidade Federal do PiauíFoundation for Research Support of the State of PiauíCompletedLow Back Pain, Recurrent | Chronic Low Back PainBrazil
-
Washington University School of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedChronic Low Back Pain | Mechanical Low Back PainUnited States
-
University of ExtremaduraCompletedChronic Low Back Pain | Postural Low Back PainSpain
-
Université du Québec à Trois-RivièresCompletedChronic Low Back Pain | Mechanical Low Back PainCanada
Clinical Trials on Placebos
-
Yiling Pharmaceutical Inc.Completed
-
Nova Scotia Health AuthorityRecruiting
-
Beth Israel Deaconess Medical CenterTerminated
-
Intra-Cellular Therapies, Inc.CompletedBipolar Depression | Major Depressive DisorderUnited States, Bulgaria, Russian Federation, Serbia, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unknown
-
GE HealthcareSyneos HealthTerminatedChronic Kidney DiseasesUnited States, Spain, Belgium, Canada, Poland, United Kingdom
-
Viela BioCTI Clinical Trial and Consulting ServicesTerminated
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Biohaven Pharmaceuticals, Inc.Active, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8United States, China
-
University Hospital, BrestEli Lilly and CompanyCompletedPolymyalgia Rheumatic (PMR)France